Similar articles

• US courts narrow patent exemptions.

  Fox JL. Fox JL. Nat Biotechnol. 2003 Aug;21(8):834. doi: 10.1038/nbt0803-834. Nat Biotechnol. 2003. PMID: 12894182 No abstract available.
• Four rebuffs for Cabilly.

  Waltz E. Waltz E. Nat Biotechnol. 2008 Apr;26(4):362. doi: 10.1038/nbt0408-362a. Nat Biotechnol. 2008. PMID: 18392001 No abstract available.
• Proposed changes to patent code loom over biotech industry.

  Coombs A. Coombs A. Nat Biotechnol. 2007 Dec;25(12):1333-4. doi: 10.1038/nbt1207-1333. Nat Biotechnol. 2007. PMID: 18066010 No abstract available.
• Patentability issues surrounding antivirals.

  Lu DL, Collison AM, Kowalski TJ. Lu DL, et al. Nat Biotechnol. 2007 Dec;25(12):1403-4. doi: 10.1038/nbt1207-1403. Nat Biotechnol. 2007. PMID: 18066035 Review. No abstract available.
• The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?

  Silbermann JM. Silbermann JM. J Contemp Health Law Policy. 1996 Spring;12(2):607-36. J Contemp Health Law Policy. 1996. PMID: 8666736 Review. No abstract available.